NovaBay Pharmaceuticals, Inc. (NYSE:NBY – Get Free Report) shares traded up 1.4% on Wednesday . The company traded as high as $2.25 and last traded at $2.16. 135,401 shares were traded during trading, a decline of 30% from the average session volume of 192,822 shares. The stock had previously closed at $2.13.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals in a research report on Monday, June 10th. They set a “hold” rating on the stock.
Read Our Latest Stock Analysis on NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Stock Down 63.1 %
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($4.90) EPS for the quarter. The company had revenue of $2.63 million during the quarter. NovaBay Pharmaceuticals had a negative return on equity of 304.39% and a negative net margin of 80.76%. As a group, analysts forecast that NovaBay Pharmaceuticals, Inc. will post -5.24 earnings per share for the current year.
Hedge Funds Weigh In On NovaBay Pharmaceuticals
An institutional investor recently bought a new position in NovaBay Pharmaceuticals stock. Armistice Capital LLC bought a new position in NovaBay Pharmaceuticals, Inc. (NYSE:NBY – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 718,768 shares of the company’s stock, valued at approximately $147,000. Armistice Capital LLC owned approximately 11.01% of NovaBay Pharmaceuticals as of its most recent SEC filing. Institutional investors own 23.25% of the company’s stock.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Featured Articles
- Five stocks we like better than NovaBay Pharmaceuticals
- Dividend Payout Ratio Calculator
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Stock Market Upgrades: What Are They?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What Are the FAANG Stocks and Are They Good Investments?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.